MO · Earnings call · 2026Q3T · Full report

Litigation and Legal Risk

ALTRIA GROUP, INC. · 2026-10-29 · Importance 52 · Surprise 42

Helix and NJOY brought legal action against the FDA during the third quarter. Their complaint asks the court to require the agency to establish a product-review process that meets the 180-day timeframe set by Congress. It also seeks to allow products with applications pending beyond that timeframe to remain on the market while the FDA establishes a new process. The transcript does not state a damages amount or quantify the financial exposure.

Key facts

• Altria said NJOY ACE had been pulled from the market because of patent issues and that it had worked around those issues.